incomplet
neutral
viru
especi
occur
presenc
excess
neutral
antibodi
repres
biolog
phenomenon
impact
greatli
antibodymedi
immun
prophylaxi
viral
infect
success
vaccin
design
understand
mechan
viru
escap
antibodymedi
neutral
investig
interact
nonneutr
neutral
antibodi
epitop
cluster
spike
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
epitop
cluster
map
cterminu
spike
protein
consist
structur
intertwin
epitop
recogn
two
neutral
monoclon
antibodi
mab
nonneutr
mab
mab
bind
mostli
linear
epitop
compos
residu
pat
v
mab
bind
epitop
partial
overlap
former
least
two
residu
p
epitop
correspond
mab
conform
one
involv
residu
l
n
neutral
assay
nonneutr
disrupt
viru
neutral
mab
andor
mab
wherea
combin
mab
block
viru
infect
synergist
find
indic
epitop
cluster
spike
protein
may
serv
evolutionarili
conserv
platform
dynam
interplay
neutral
nonneutr
antibodi
occur
therebi
determin
outcom
sarscov
infect
publish
elsevi
inc
correspond
author
fax
email
address
lilinzhong
fdahhsgov
l
zhong
cdcgov
l
hayn
evistrubl
fdahhsgov
eb
strubl
atamin
cdcgov
tamin
marialuisa
virata
fdahhsgov
ml
viratatheim
peizhang
fdahhsgov
p
zhang
patient
suffer
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
often
appreci
level
virusspecif
antibodi
situat
similar
encount
viral
diseas
chronic
hepat
c
hiv
infect
persist
despit
presenc
antibodi
one
mechan
propos
origin
dulbecco
et
al
account
appar
inhibit
viru
neutral
serum
infect
individu
might
contain
nonneutr
antibodi
combin
correspond
viru
nonneutr
antibodi
could
presum
interfer
attach
neutral
antibodi
therebi
diminish
neutral
activ
massey
schochetman
subsequ
show
nonneutr
antibodi
bind
viru
steric
block
bind
neutral
antibodi
recent
found
two
epitop
ii
within
short
peptid
hypervari
region
ii
hepat
c
viru
protein
epitop
epitop
ii
implic
viru
neutral
bind
nonneutr
antibodi
epitop
ii
disrupt
viru
neutral
mediat
antibodi
bind
epitop
investig
whether
similar
occurr
name
presenc
nonneutr
antibodi
along
neutral
antibodi
could
account
observ
sarscov
surviv
despit
vigor
antibodi
respons
host
character
three
previous
isol
monoclon
antibodi
mab
recogn
spike
protein
sarscov
residu
found
two
neutral
mab
could
act
synergist
inhibit
sarscov
infect
vitro
nonneutr
antibodi
disrupt
neutral
activ
find
suggest
epitop
cluster
may
provid
viral
escap
mechan
wherebi
neutral
viru
thwart
interf
nonneutr
antibodi
cell
mab
epitop
mab
locat
within
residu
spike
protein
mab
use
present
studi
similar
describ
previous
viru
stock
microneutr
assay
vero
cell
maintain
dmem
supplement
heatinactiv
fetal
bovin
serum
mm
lglutamin
urbani
strain
sarscov
plaquepurifi
grown
stock
titer
vero
cell
purifi
polyethylen
glycol
peg
precipit
describ
previous
frozen
use
microneutr
assay
perform
previous
describ
microneutr
titer
test
antibodi
highest
dilut
show
inhibit
triplic
well
control
includ
assay
perform
includ
back
titrat
inclus
posit
control
antibodi
ie
serum
convalesc
sar
patient
isotyp
monoclon
antibodi
control
data
obtain
least
three
independ
experi
analyz
peptid
synthesi
peptid
synthes
core
laboratori
center
biolog
evalu
research
food
drug
administr
appli
biosystem
foster
citi
ca
model
peptid
synthes
use
standard
fastmoc
chemistri
elisa
streptavidinco
plate
use
elisa
accord
manufactur
instruct
pierc
rockford
il
briefli
biotinyl
peptid
ngwell
ad
streptavidinco
well
block
block
buffer
h
wash
pb
tween
pbst
primari
antibodi
ad
well
incub
min
remov
unbound
antibodi
wash
pbst
goat
antimous
peroxidaseconjug
igg
kpl
gaithersburg
md
dilut
ad
well
incub
min
wash
tetramethylbenzidin
substrat
pierc
ad
plate
incub
room
temperatur
dark
min
reaction
termin
ad
n
sulfur
acid
absorb
nm
measur
optimax
molecular
devic
palo
alto
ca
phage
display
select
peptid
random
peptid
phage
display
librari
new
england
biolab
beverli
describ
previous
briefli
phage
incub
individu
antibodyprotein
g
mixtur
min
room
temperatur
eight
wash
trishcl
buffer
ph
contain
nacl
tween
phage
elut
complex
hcl
min
room
temperatur
neutral
trishcl
ph
elut
phage
amplifi
host
strain
three
addit
round
select
amplifi
phage
dna
singlephag
plaqu
sequenc
correspond
peptid
sequenc
deduc
dna
sequenc
structur
analysi
structur
analysi
perform
use
coordin
sarscov
receptorbind
domain
rbd
ie
pdb
id
among
structur
pdb
id
complet
assign
ctermin
region
rbd
encompass
residu
antibodi
bind
structur
visual
manipul
use
program
pymol
statist
analysi
jmp
softwar
sa
institut
cari
nc
use
analyz
data
pairwis
comparison
mean
peptid
mutat
perform
use
student
ttest
p
consid
statist
signific
overal
comparison
mean
tukeykram
hsd
test
use
statist
signific
set
posit
test
valu
gener
two
mean
indic
signific
differ
attempt
identifi
residu
within
fragment
critic
antibodi
recognit
peptid
encompass
residu
chemic
synthes
elisa
analysi
show
mab
capabl
recogn
synthet
peptid
wherea
mab
unabl
bind
fig
result
suggest
epitop
correspond
mab
like
linear
epitop
consist
residu
within
peptid
character
epitop
mab
antibodi
made
use
previous
publish
structur
inform
spike
protein
guid
synthesi
set
peptid
contain
specif
mutat
fig
replac
n
rr
peptid
span
residu
detect
effect
bind
mab
suggest
neither
n
involv
epitop
mab
howev
singl
mutat
p
r
result
signific
loss
bind
mab
p
fig
similarli
reduct
bind
observ
follow
replac
v
rr
p
fig
result
indic
residu
p
well
andor
v
within
peptid
import
mab
fig
epitop
map
epitop
map
elisa
one
hundr
nanogram
biotinlabel
peptid
wt
ad
streptavidinco
plate
elisa
xaxi
indic
differ
mous
monoclon
antibodi
control
yaxi
indic
absorb
nm
elisa
absorb
mab
compar
mab
mab
control
antibodi
test
result
shown
column
p
consid
signific
b
peptid
mutant
amino
acid
sequenc
encompass
residu
wt
mutat
na
rr
p
r
tv
rr
indic
c
elisa
peptid
mutant
biotinlabel
peptid
ngwell
defin
wt
mutant
na
rr
p
r
tv
rr
respect
ad
streptavidinco
plate
mab
dilut
react
wt
peptid
use
probe
xaxi
indic
peptid
use
assay
yaxi
indic
absorb
nm
repres
specif
bind
mab
individu
peptid
test
result
wt
mutant
comparison
shown
column
p
consid
signific
recognit
inde
insert
residu
napatv
synthet
peptid
deriv
hcv
protein
confirm
napatv
alon
could
recogn
mab
inabl
mab
bind
synthet
peptid
impli
epitop
might
conform
natur
map
epitop
correspond
mab
random
peptid
phage
display
librari
use
two
commerci
avail
librari
use
present
studi
librari
display
amino
acid
flank
two
cystein
residu
permit
format
disulfid
bond
configur
peptid
residu
present
loop
structur
allow
recogn
singl
antibodi
complement
approach
screen
peptid
librari
antibodi
could
assist
identifi
core
sequenc
defin
least
two
connect
residu
within
display
peptid
highli
similar
ident
linear
sequenc
spike
protein
found
p
v
key
residu
present
select
peptid
follow
screen
librari
mab
fig
librari
screen
three
connect
residu
apa
found
core
sequenc
fig
linear
residu
found
peptid
abl
determin
epitop
correspond
compos
residu
apa
fig
v
expos
surfac
rather
buri
insid
structur
spike
protein
thu
make
inaccess
antibodi
bind
survey
valin
residu
locat
proxim
core
sequenc
apa
found
virtu
particular
fold
spike
protein
v
situat
close
apa
result
uniqu
posit
v
make
ideal
structur
substitut
buri
side
chain
v
fig
find
provid
rational
includ
v
propos
bind
site
mab
wherea
residu
p
l
found
critic
bind
mab
use
librari
fig
patl
reveal
core
sequenc
librari
nearli
ident
patv
identifi
residu
involv
bind
mab
fig
know
v
neither
expos
surfac
solventaccess
argu
v
rather
v
key
residu
mab
bind
addit
found
p
share
residu
recogn
mab
possibl
competit
two
function
distinct
mab
therefor
rais
similarli
librari
screen
use
mab
phagedisplay
peptid
contain
key
residu
n
p
l
subsequ
screen
suggest
residu
nm
l
pl
core
sequenc
mab
fig
b
data
indic
residu
l
n
residu
mab
bind
interestingli
analysi
structur
spike
protein
reveal
sever
residu
includ
p
l
ie
three
identifi
phage
display
expos
surfac
locat
loop
adjac
epitop
mab
fig
peculiar
configur
may
provid
extend
interfac
addit
residu
l
n
bind
mab
structur
studi
need
confirm
supposit
spatial
relationship
among
three
epitop
analyz
structur
model
fig
first
observ
three
identifi
epitop
form
close
pack
cluster
thu
locat
proxim
surfac
spike
protein
fig
yet
distal
receptor
bind
site
epitop
mab
partial
overlap
mab
least
two
amino
acid
ie
p
presum
compet
residu
fig
nonneutr
antibodi
mab
could
inhibit
bind
neutral
mab
equilibriumrel
fashion
second
epitop
mab
also
locat
close
proxim
recogn
mab
bind
mab
may
block
access
mab
fig
larg
surfac
area
antigen
often
buri
upon
antibodi
bind
davi
cohen
calcul
buri
area
rang
encompass
amino
acid
residu
although
amino
acid
ie
epitop
make
direct
contact
antibodi
thu
upon
antibodi
bind
buri
surfac
area
contain
epitop
region
undergo
direct
interact
antibodi
includ
also
area
adjac
epitop
region
plu
area
solvent
access
block
antibodi
occupi
surfac
antigen
third
although
epitop
mab
locat
singl
loop
spike
protein
spatial
separ
therebi
provid
distinct
interfac
independ
antibodi
bind
fig
cluster
epitop
prompt
us
examin
function
interact
correspond
mab
measur
viru
neutral
assay
tabl
show
result
obtain
least
three
independ
neutral
experi
use
three
mab
independ
andor
combin
expect
mab
show
neutral
mab
alon
neutral
viru
infect
titer
respect
neutral
titer
rose
mab
mix
directli
viru
ask
whether
nonneutr
mab
could
interfer
neutral
activ
mab
alon
combin
mab
tabl
demonstr
result
least
three
independ
neutral
assay
mab
mix
sarscov
neutral
titer
mab
reduc
tabl
direct
mix
similarli
presenc
also
reduc
neutral
titer
mab
tabl
direct
mix
neutral
activ
mixtur
three
antibodi
lower
two
neutral
antibodi
tabl
direct
mix
result
demonstr
nonneutr
mab
interfer
viru
neutral
mediat
mab
andor
mab
final
ask
whether
stepwis
mix
three
mab
rather
concomitantli
mix
viral
stock
would
make
differ
neutral
titer
shown
tabl
stepwis
mix
signific
differ
neutral
titer
mab
ad
sequenti
compar
ad
individu
antibodi
viral
inoculum
simultan
studi
impli
mab
similar
bind
affin
toward
specif
epitop
may
act
equilibriumrel
manner
studi
identifi
cluster
epitop
spike
protein
sarscov
within
cluster
interplay
occur
among
nonneutr
neutral
antibodi
first
antibodyspecif
epitop
spatial
close
arrang
creat
uniqu
platform
competit
one
possibl
mechan
steric
block
nonneutr
antibodi
reduc
amount
virionbound
neutral
antibodi
spike
protein
suboptim
level
occup
disabl
neutral
conclud
klass
cowork
studi
human
anim
virus
condit
report
west
nile
viru
antibodymedi
neutral
achiev
rel
high
concentr
virionbound
antibodi
wherea
enhanc
infect
observ
lower
concentr
conform
trigger
entri
function
complementor
fc
receptordepend
mechan
steric
interfer
mab
mab
propos
mechan
residu
share
spatial
occup
residu
cyan
bound
mab
residu
magenta
bound
mab
residu
brown
share
one
bind
antibodi
c
steric
interfer
mab
mab
propos
mechan
spatial
occup
residu
cyan
bound
mab
residu
orang
bound
mab
structur
mechanist
model
synergist
viru
neutral
mab
mab
residu
magenta
bound
mab
residu
orang
bound
mab
second
although
epitop
neutral
mab
situat
spatial
close
partli
share
singl
loop
structur
repres
two
separ
interfac
antibodi
bind
synergist
neutral
observ
mix
experi
may
thu
understood
two
antibodi
abl
bind
respect
epitop
without
competit
third
residu
two
neutral
epitop
mab
directli
involv
bind
receptor
find
unpreced
antibodi
specif
influenza
hemagglutinin
neutral
bind
outsid
viru
receptor
bind
site
addit
altern
auxiliari
receptor
sarscov
could
exist
studi
whether
mab
mab
suffici
block
receptor
bind
site
bind
mab
caus
subtl
indirect
conform
chang
rbd
provid
insight
mechan
synergi
final
creat
close
pack
epitop
cluster
viru
elicit
nonneutr
antibodi
block
bind
neutral
antibodi
mechan
oper
vivo
provid
explan
immun
evas
virus
regardless
whether
viru
caus
acut
chronic
infect
hand
may
also
possibl
host
mount
vigor
neutral
antibodi
respons
viru
infect
produc
antibodi
recogn
distinct
epitop
act
synergist
understand
mechan
antibodi
synergi
interfer
could
serv
prerequisit
design
effect
vaccin
develop
effect
immun
prophylact
treatment
viru
infect
